Inavir laninamivir: Completed Phase III enrollment

Biota said Daiichi Sankyo completed enrollment in a double-blind, placebo-controlled, Japanese Phase III trial evaluating 2 doses of Inavir laninamivir in about 1,500 healthy family members of a patie...